AB Science Stock

AB Science Debt 2024

AB Science Debt

13.09 EUR

Ticker

AB.PA

ISIN

FR0010557264

WKN

A1CXBG

In 2024, AB Science's total debt was 13.09 EUR, a -37.86% change from the 21.07 EUR total debt recorded in the previous year.

AB Science Aktienanalyse

What does AB Science do?

AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding AB Science's Debt Structure

AB Science's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing AB Science's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to AB Science’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in AB Science’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about AB Science stock

What is the debt of AB Science this year?

AB Science has a debt level of 13.09 EUR this year.

What was the debt of AB Science compared to the previous year?

The debt of AB Science has increased by -37.86% compared to the previous year dropped.

What are the consequences of high debt for investors in AB Science?

High debt can pose a risk for investors of AB Science, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of AB Science?

Low debt means that AB Science has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from AB Science affect the company?

An increase in debt of AB Science can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of AB Science affect the company?

A reduction in debt of AB Science can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of AB Science?

Some factors that can influence the debt of AB Science include investments, acquisitions, operating costs, and revenue development.

Why are the debts of AB Science so important for investors?

The debts of AB Science are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can AB Science take to change the debt?

To change the debt, AB Science can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does AB Science pay?

Over the past 12 months, AB Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AB Science is expected to pay a dividend of 0 EUR.

What is the dividend yield of AB Science?

The current dividend yield of AB Science is .

When does AB Science pay dividends?

AB Science pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AB Science?

AB Science paid dividends every year for the past 0 years.

What is the dividend of AB Science?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is AB Science located?

AB Science is assigned to the 'Health' sector.

Wann musste ich die Aktien von AB Science kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AB Science from 9/29/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did AB Science pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of AB Science in the year 2023?

In the year 2023, AB Science distributed 0 EUR as dividends.

In which currency does AB Science pay out the dividend?

The dividends of AB Science are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The AB Science stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von AB Science

Our stock analysis for AB Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.